Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676715 | 1.00 | KMO (0.71) | KMOTSHRSLC6A4SLC6A3HSD11B1 | |
| SCHEMBL3670105 | 1.00 | KMO (0.71) | KMOTSHRSLC6A4SLC6A3HSD11B1 | |
| SCHEMBL19642672 | 0.86 | KMO (0.75) | KMOTSHRSLC6A4SLC6A3HSD11B1 | |
| SCHEMBL4386002 | 0.83 | KMO (1.00) | KMOTSHRSLC6A4SLC6A3 | |
| SCHEMBL728113 | 0.83 | KMO (1.00) | KMOTSHRSLC6A4SLC6A3 | |
| SCHEMBL3670421 | 0.83 | KMO (1.00) | KMOTSHRSLC6A4SLC6A3 | |
| SCHEMBL7797590 | 0.81 | KMO (1.00) | KMOTSHRSLC6A4SLC6A3 | |
| SCHEMBL7399077 | 0.81 | KMO (0.69) | KMOTSHRSLC6A4SLC6A3HSD11B1 | |
| SCHEMBL7797593 | 0.81 | KMO (1.00) | KMOTSHRSLC6A4SLC6A3 | |
| SCHEMBL3671146 | 0.81 | KMO (0.69) | KMOTSHRSLC6A4SLC6A3GRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | claimed |
| US-7727977-B2 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| US-6323240-B1 | HALOGENATED DERIVATIVES AS ENZYME INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-11-27 | — | — | US | disclosed |
| EP-0858443-A1 | 4-PHENYL-4-OXO-BUTANOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017317-A1 | 4-PHENYL-4-OXO-BUTANOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | KYNU, KMO, IDO1 | KMO 2/4885TSHR 2567/4885SLC6A4 1436/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | KMO 2/4885TSHR 2294/4885SLC6A4 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.